X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
taspoglutide (29) 29
humans (23) 23
index medicus (23) 23
type 2 diabetes (17) 17
diabetes mellitus, type 2 - drug therapy (15) 15
exenatide (15) 15
glycemic control (14) 14
glucagon-like peptide-1 (13) 13
liraglutide (13) 13
albiglutide (12) 12
metformin (12) 12
diabetes (11) 11
double-blind (11) 11
endocrinology & metabolism (11) 11
hypoglycemic agents - administration & dosage (11) 11
male (11) 11
peptides - administration & dosage (11) 11
pharmacology & pharmacy (11) 11
female (10) 10
hypoglycemic agents - adverse effects (10) 10
hypoglycemic agents - therapeutic use (10) 10
safety (10) 10
middle aged (9) 9
adult (8) 8
body-weight (8) 8
drug administration schedule (8) 8
glucagon-like peptide-1 receptor (8) 8
treatment outcome (8) 8
animals (7) 7
receptors, glucagon - agonists (7) 7
analysis (6) 6
diabetes mellitus, type 2 - blood (6) 6
diabetes mellitus, type 2 - metabolism (6) 6
hypoglycemic agents - pharmacology (6) 6
open-label (6) 6
peptides (6) 6
peptides - adverse effects (6) 6
peptides - therapeutic use (6) 6
randomized controlled trials as topic (6) 6
type 2 diabetes mellitus (6) 6
blood glucose - drug effects (5) 5
clinical trials (5) 5
efficacy (5) 5
glp-1 (5) 5
glp-1 agonist (5) 5
glucagon (5) 5
glucagon-like peptide 1 - administration & dosage (5) 5
glucagon-like peptide 1 - analogs & derivatives (5) 5
human glp-1 analog (5) 5
peptides - pharmacology (5) 5
sitagliptin (5) 5
type-2 (5) 5
venoms - administration & dosage (5) 5
double-blind method (4) 4
glp-1 receptor agonist (4) 4
glucagon-like peptide 1 - pharmacology (4) 4
glucose (4) 4
hypoglycemic agents (4) 4
hypoglycemic agents - pharmacokinetics (4) 4
metformin - therapeutic use (4) 4
peptides - pharmacokinetics (4) 4
pharmacodynamics (4) 4
tolerability (4) 4
treated patients (4) 4
adolescent (3) 3
aged (3) 3
beta-cell function (3) 3
clinical trials, phase iii as topic (3) 3
dextrose (3) 3
diabetes mellitus (3) 3
diabetes therapy (3) 3
diabetic-patients (3) 3
dose-response relationship, drug (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
glp-1 analog (3) 3
glucagon-like peptide 1 - agonists (3) 3
glycated hemoglobin a - metabolism (3) 3
glycosylated hemoglobin (3) 3
hyperglycemia (3) 3
injections, subcutaneous (3) 3
internal medicine (3) 3
lixisenatide (3) 3
nausea - chemically induced (3) 3
obesity (3) 3
pharmacokinetics (3) 3
pioglitazone (3) 3
rodents (3) 3
therapy (3) 3
twice-daily exenatide (3) 3
type-2 diabetes-mellitus (3) 3
venoms - therapeutic use (3) 3
weight loss (3) 3
alogliptin (2) 2
analog (2) 2
analog taspoglutide (2) 2
biochemical research methods (2) 2
blood glucose - metabolism (2) 2
chemistry, analytical (2) 2
chemistry, multidisciplinary (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Archives of Hellenic Medicine, ISSN 1105-3992, 09/2015, Volume 32, Issue 5, pp. 535 - 545
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 317 - 332
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2011, Volume 13, Issue 5, pp. 394 - 407
Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4)... 
albiglutide | GLP‐1 analogue | CJC‐1134‐PC | GLP‐1 receptor agonists | antidiabetic drug | type 2 diabetes mellitus | LY2189265 | taspoglutide | exenatide once weekly | incretin therapy | Incretin therapy | Exenatide once weekly | Antidiabetic drug | GLP-1 receptor agonists | GLP-1 analogue | Taspoglutide | CJC-1134-PC | Albiglutide | Type 2 diabetes mellitus | HUMAN GLP-1 ANALOG | INSULIN-SECRETION | OPEN-LABEL | INADEQUATE GLYCEMIC CONTROL | TWICE-DAILY EXENATIDE | BODY-WEIGHT | BETA-CELL-FUNCTION | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ACUTE-PANCREATITIS | TYPE-2 DIABETES-MELLITUS | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - pharmacology | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Hyperglycemia - drug therapy | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Glucagon-Like Peptides - analogs & derivatives | Recombinant Fusion Proteins - administration & dosage | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Biomarkers - blood | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Glucagon-Like Peptide-1 Receptor | Immunoglobulin Fc Fragments - pharmacology | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Antigen-antibody reactions | Hyperglycemia | Peptides | Heterocyclic compounds | Glycosylated hemoglobin | Hypoglycemic agents | Glucose | Dextrose
Journal Article
ANNALS OF PHARMACOTHERAPY, ISSN 1060-0280, 05/2010, Volume 44, Issue 5, pp. 904 - 909
OBJECTIVE: To review the possible association between glucagon-like peptide-1 (GLP-1) agonist use and pancreatitis in patients with type 2 diabetes mellitus.... 
liraglutide | METFORMIN | GLYCEMIC CONTROL | SULFONYLUREA | EXENATIDE EXENDIN-4 | taspoglutide | TREATED PATIENTS | albiglutide | BODY-WEIGHT | type 2 diabetes | GLP-1 agonist | LIRAGLUTIDE NN2211 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | pancreatitis | GLP-1 ANALOG | TYPE-2 | exenatide
Journal Article
Journal Article
Journal Article
Journal of Chromatography A, ISSN 0021-9673, 2011, Volume 1218, Issue 39, pp. 6953 - 6960
Random PEGylation usually resulted in product mixtures composed of mono-PEGylated isomers and multie-PEGylated attachments. Generally in PEGylation research,... 
Exenatide analogue | Polyethylene glycol | Cation exchange chromatography | CHEMISTRY, ANALYTICAL | IN-VITRO | INTERFERON ALPHA-2A | GLP-1 | PROTEIN | GLUCAGON-LIKE PEPTIDE-1 | POSITIONAL ISOMERS | BIOCHEMICAL RESEARCH METHODS | TASPOGLUTIDE | Separation | Analogue | Cation exchanging | Hydrophobicity | Isomers | Chromatography | Optimization
Journal Article
Journal of the American Pharmacists Association, ISSN 1544-3191, 09/2009, Volume 49, Issue 5, pp. S16 - S29
To review the pharmacology (absorption, metabolism, distribution, elimination, and contraindications) of incretin-based agents currently available and in... 
Type 2 diabetes | liraglutide | albiglutide | incretins | sitagliptin | vildagliptin | alogliptin | saxagliptin | taspoglutide | exenatide | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | HEALTHY-SUBJECTS | LOWERS BODY-WEIGHT | BETA-CELL FUNCTION | DRUG-NAIVE PATIENTS | GLUCAGON-LIKE PEPTIDE-1 | NUTRITION EXAMINATION SURVEY | IMPROVES GLYCEMIC CONTROL | IV INHIBITOR | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Dipeptidyl Peptidase 4 - metabolism | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Incretins - metabolism | Molecular Sequence Data | Structure-Activity Relationship | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Insulin-Secreting Cells - metabolism | Molecular Structure | Receptors, Glucagon - agonists | Satiety Response - drug effects | Amino Acid Sequence | Hypoglycemic Agents - pharmacokinetics | Receptors, Glucagon - metabolism | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Treatment Outcome | Hypoglycemic Agents - chemistry | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Insulin - metabolism | Animals | Diabetes Mellitus, Type 2 - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Glucagon-Like Peptide-1 Receptor | Insulin-Secreting Cells - drug effects | Gastric Emptying - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects
Journal Article